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Background: Ruscogenin is a major steroid sapogenin in the traditional Chinese herb Ophiopogon japonicus that have
multiple bioactivities. Recent studies have demonstrated that ruscogenin is involved in down-regulation of intercellular
adhesion molecule-1 (ICAM-1) and nuclear factor-κB (NF-κB) activation in anti-inflammatory pathways. We hypothesized
that ruscogenin protects against diabetic nephropathy (DN) by inhibiting NF-κB-mediated inflammatory pathway. To test
this hypothesis, the present study was to examine the effects of ruscogenin in rats with streptozotocin (STZ)-induced DN.
Methods: Diabetes was induced with STZ (60 mg/kg) by intraperitoneal injection in rats. Two weeks after STZ injection,
rats in the treatment group were orally dosed with 0.3, 1.0 or 3.0 mg/kg ruscogenin for 8 weeks. The normal rats were
chosen as nondiabetic control group. The rats were sacrificed 10 weeks after induction of diabetes. Changes in renal
function-related parameters in plasma and urine were analyzed at the end of the study. Kidneys were isolated for
pathology histology, immunohistochemistry, and Western blot analyses.
Results: Ruscogenin administration did not lower the levels of plasma glucose and glycosylated hemoglobin in
STZ-diabetic rats. Diabetic rats exhibited renal dysfunction, as evidenced by reduced creatinine clearance, blood
urea nitrogen and proteinuria, along with marked elevation in the ratio of kidney weight to body weight, that were
reversed by ruscogenin. Ruscogenin treatment was found to markedly improve histological architecture in the diabetic
kidney. Renal NF-κB activity, as wells as protein expression and infiltration of macrophages were increased in
diabetic kidneys, accompanied by an increase in protein content of intercellular adhesion molecule-1 and monocyte
chemoattractant protein-1 in kidney tissues. All of the above abnormalities were reversed by ruscogenin treatment,
which also decreased the expression of transforming growth factor-β1 and fibronectin in the diabetic kidneys.
Conclusions: Our data demonstrated that ruscogenin suppressed the inflammation and ameliorated the structural
and functional abnormalities of the diabetic kidney in rats might be associated with inhibition of NF-κB mediated
inflammatory genes expression.Background
It is increasingly apparent that not only is a cure for the
current worldwide diabetes epidemic required, but also for
its major complications, affecting both small and large
blood vessels. These complications occur in the majority
of individuals with both type 1 and type 2 diabetes [1].
Diabetic nephropathy (DN) is a serious complication in
diabetes. Major typical morphological changes are the* Correspondence: mcwu@mail.npust.edu.tw; iml@mail.tajen.edu.tw
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unless otherwise stated.result of changes in the extracellular matrix (ECM). The
ECM accumulation in DN results in mesangial expansion,
tubulointerstitial fibrosis, and irreversible deterioration of
renal function [2]. Even though previous studies have
shown that ECM accumulation under diabetic conditions
is attributable to hyperglycemia, hemodynamic changes,
and local growth factors such as angiotensin II and trans-
forming growth factor (TGF)-β1, the precise molecular
and cellular mechanisms responsible for this have yet to
be resolved [1]. Clarification of the pathogenesis of DN
and development of novel and effective therapeutic strat-
egies are therefore high priorities.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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inflammatory disease, recent studies have shown that
kidney inflammation is crucial in promoting the devel-
opment and progression of DN [3,4]. It has demon-
strated that macrophage infiltration into glomeruli is
associated with the progression of DN [5]. Monocyte
chemotactic protein-1 (MCP-1) and intercellular adhe-
sion molecule-1 (ICAM-1), which make the monocytes/
macrophages extravasculate from the blood-stream and
attract to the kidney tissue, promote the development
of DN [6,7]. Nuclear factor (NF)-κB, which regulates
genes encoding proinflammatory mediators, involves
in the inflammatory processes, and the activation of
NF-κB and the transcription of certain proinflammatory
chemokines have been demonstrated as the markers of
progressive DN in patients [8]. These studies strongly
suggest that NF-κB-mediated inflammatory processes
represent a novel mechanism leading to DN. Therefore,
it may be a novel therapy strategy for DN to reduce
renal inflammation.
Ruscogenin (1β,3β,25R)-Spirost-5-ene-1,3-diol), first iso-
lated from Ruscus aculeatus, has been reported to exert
robust anti-inflammatory activities. It acts as an anti-
elastase, decreases capillary permeability, and is widely
used to treat chronic venous insufficiency and vasculitis
[9-11]. In addition, ruscogenin is also a major steroidal sa-
pogenin of the traditional Chinese herb Radix Ophiopogon
japonicus, which has been clinically used to treat acute
and chronic inflammatory and cardiovascular diseases
[12,13]. Previous research has proved that the possible
anti-inflammatory mechanism of ruscogenin was linked
with the suppression of ICAM-1 expression in endothelial
cells mainly through the inhibition of the NF-κB signaling
pathway [14]. It was also found that ruscogenin signifi-
cantly attenuated lipopolysaccharide (LPS)-induced acute
lung injury model in mice, which possibly linked with in-
hibition of NF-κB activation [15]. Such activities of rusco-
genin indicate its potential protection in diabetic kidney;
however, there is no report about it until now.
Analyses of renal biopsies from type 1 and type 2 dia-
betic patients who develop DN indicate that inflamma-
tory infiltrates are similar in both groups [16], which
is consistent with studies in diabetic animal models
[17,18]. To characterize its efficacy in the present study,
ruscogenin was administered orally to streptozotocin-
(STZ) induced diabetic rats for eight consecutive weeks.
We present the results of this study and discuss the pos-
sible underlying action mechanism of this compound
on diabetic renal lesions.
Methods
Animal models
Male Wistar rats (8 to 10 weeks of age, 200–250 g) were
obtained from the Animal Center of National Cheng KungUniversity Medical College. To induce diabetes rats were
given a single intravenous injection of 60 mg/kg strepto
zotocin (STZ; Sigma-Aldrich, Inc., St. Louis, Mo., USA).
Animals were considered to be diabetic if they had plasma
glucose concentrations of 350 mg/dl or greater, in addition
to polyuria and other diabetic features. All studies were
carried out two weeks after the injection of STZ. All
animal procedures were performed according to the
Guidelines for the Care and Use of Laboratory Animals
of the National Institutes of Health (United States), as
well as the guidelines of the Animal Welfare Act. The
study was conducted with the approval of the Institu-
tional Animal Care and Use Committee (IACUC) at
Tajen University (approval number: IACUC 99–24; ap-
proval date: December 23, 2011).
Treatment protocols
STZ-diabetic rats in the treatment group were dosed
with 0.3, 1.0 or 3.0 mg/kg ruscogenin (≥ 98%; Chengdu
Biopurify Phytochemicals Ltd., Chengdu, Sichuan, China;
Cat. No. 472-11-7) in distilled water (1.5 ml/kg) by oral
gavage once daily for eight weeks. The dosage regimen
was selected based on a previous report demonstrating
that ruscogenin at the indicated dosage regimen was po-
tentially effective in inhibiting lipopolysaccharide-induced
inflammation in mice [15]. Another group of STZ-diabetic
rats was treated orally for eight weeks with 5 mg/kg/day
rosiglitazone (purity ≥ 99.0%, Sigma-Aldrich, Inc.). The
dose of rosiglitazone was based on studies with long-term
treatment in STZ-diabetic rats [19]. A vehicle-treated
groups of STZ-diabetic rats and normal rats were give 1.5
ml/kg distilled water by oral gavage over the same period.
Animals had free access to standard rat diet (Harlan
Teklad, Madison, WI, USA; Cat. No. 2018) and water
throughout the entire treatment period. Treatment was
continued even though the plasma glucose of STZ-
diabetic rats was lower than 350 mg/dl during the eight-
week treatment period. At the end of the eight-week
treatment, the rats were weighed, and blood samples
were collected from a tail vein. The evening prior to
blood sample collection, animals were restricted to 3 g
of chow (given at 18:00 h), which was consumed immedi-
ately, and thereafter had access to only water. The animals
were transferred to metabolic cages (Shineteh Instruments
Co., Ltd, Taipei, Taiwan), and urine was collected for 24
hours under a layer of toluene (to inhibit bacteria growth)
and stored at 4°C for later analysis. Toluene had no detect-
able effect on the estimation of albumin and creatinine in
the urine samples. Following urine collection, rats were
sacrificed using an intraperitoneal injection of sodium
pentobarbital (50 mg/kg).
The kidneys were dissected and rinsed with cold iso-
tonic saline and weighed. The right kidney was stored
immediately at −80°C in liquid nitrogen for biochemical
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ney tissues were fixed in 10% neutralized formalin for
histology.Blood sampling and analysis
Blood samples were centrifuged at 2 000 × g for 10 minutes
at 4°C, and plasma was divided into aliquots for subse-
quent analyses. Plasma glucose concentration was deter-
mined using a diagnostic kit from BioSystem (Barcelona,
Spain; Cat. No. COD12503). Serum creatinine (Scr)
concentration was determined using a commercial assay
kit purchased from Diagnostic Chemicals Limited
(Connecticut, USA; Cat. No. 221–30). Blood urea nitrogen
(BUN) was determined by kinetic reagent (Diagnostic
Chemicals Limited, Cat. No. 283–30). Commercial
enzyme-linked immunosorbent assay kits were used to
quantify glycosylated hemoglobin (HbA1c) levels (Inte-
grated Bio Ltd., Taipei, Taiwan; Cat. No. CSB-E08140r).
All analyses were performed in accordance with the in-
structions provided by the manufacturers.Analysis of urine parameters
The 24-hour urine samples collected from each diabetic rat
and age-matched control was centrifuged at 2 000 × g for
10 minutes. Urinary albumin concentrations were mea-
sured with the Nephrat II ELISA kit (Exocell, PA, USA;
Cat. No. NR002). The concentration of creatinine in pooled
urine samples was determined using a commercial assay kit
(Diagnostic Chemicals Limited; Cat. No. 221–30). All ana-
lyses were performed in accordance with the manufac-
turer’s instructions. Creatinine clearance (Ccr) was
calculated in individual rats using the relationship: Ccr =Table 1 Body and kidney weights, index of renal hypertrophy




Body weight (BW) (g/rat) 374.88 ± 17.92d 214.84 ± 14.95b 237.3
Plasma glucose (mg/dl) 92.78 ± 7.32d 423.12 ± 16.22b 418.2
HbAlc (%) 4.79 ± 1.03d 14.32 ± 1.79b 14.10
Kidney weight (KW) (g/rat) 1.38 ± 0.17d 2.28 ± 0.15b 2.07
KW/BW ratio (%) 0.37 ± 0.07d 1.06 ± 0.08b 0.87
24-h urine volume (ml/day) 8.96 ± 1.76d 27.30 ± 2.95b 21.84
24-h urine protein (mg/day) 6.60 ± 2.57d 28.36 ± 3.95b 24.11
Scr (μmol/l) 34.07 ± 5.26d 87.23 ± 7.96b 70.33
BUN (mmol/l) 6.51 ± 0.82d 18.85 ± 1.13b 15.68
Ccr (ml/min) 4.83 ± 0.63d 1.78 ± 0.71b 2.14
STZ-diabetic rats were dosed by oral gavage once per day for eight weeks with rus
receiving vehicle treatment were given the same volume of vehicle (distilled water)
group of 8 animals. aP < 0.05 and bP < 0.01 compared to the values of vehicle-treate
vehicle-treated STZ-diabetic rats, respectively.urine creatinine × (urine volume/plasma creatinine) × time
[20].
NF-κB activity measurement
Nuclear extracts of kidney from the above-mentioned
groups were prepared using the nuclear extract kit (Active
Motif, CA, USA; Cat. No. 40010). Twenty micrograms of
nuclear extract were used for the determination of NF-κB
activity with the TransAM® NF-κB p65 transcription factor
assay kit (Active Motif; Cat. No. 40096) according to the
manufacturer’s instruction.
Renal cytokines determination
Renal tissue was homogenized in 10 mmol/L Tris–HCl
buffered solution (pH 7.4) containing 2 mol/L NaCl,
1 mmol/L EDTA, 0.01% Tween 80, 1 mmol/L PMSF, and
centrifuged at 9 000 × g for 30 min at 4°C [21]. The result-
ant supernatant was used for cytokine determination.
ELISA kits for the determination of tumor necrosis factor-α
(TNF-α) (Cat. No. ab46070), interleukin (IL)-6 (Cat. No.
ab100772), and IL-1β (Cat. No. ab100768) were obtained
from Abcam Inc. (Cambridge, MA, USA). Samples were
assayed in duplicates according to manufacturer's in-
structions. The protein concentrations of kidney filtrate
were determined using a Bio-Rad protein assay kit (Bio-
Rad Laboratories, Japan) and bovine serum albumin
(BSA) as a standard.
Renal histological analysis
For histological analysis, the kidney was removed and
embedded in paraffin to prepare 4-μm tissue slices. The
tissue slices were stained with hematoxylin and eosin




± 17.21b 261.98 ± 18.32b,c 291.64 ± 16.24b,c 315.18 ± 18.10a,d
7 ± 15.34b 412.37 ± 17.41b 409.87 ± 14.68b 262.31 ± 13.71b,c
± 1.63b 13.92 ± 1.84b 13.85 ± 1.65b 9.63 ± 1.59b,c
± 0.13b 1.93 ± 0.21b 1.85 ± 0.19a,c 1.79 ± 0.18a,d
± 0.09b 0.74 ± 0.06b,c 0.62 ± 0.04a,d 0.57 ± 0.05a,d
± 3.11b 19.65 ± 2.43b,c 17.65 ± 3.05a,c 15.34 ± 2.62a,c
± 3.25b 19.85 ± 2.57,c 14.82 ± 3.29 a,d 10.26 ± 4.12a,d
± 5.83b,c 69.78 ± 4.92b,c 62.21 ± 5.61b,c 56.49 ± 6.92b,c
± 1.25b,c 14.27 ± 1.38b,c 12.66 ± 0.94b,c 9.71 ± 1.02a,c
± 0.56b 2.92 ± 0.61b 3.43 ± 0.59a,c 3.71 ± 0.74d
cogenin at the indicated dosage, or rosiglitazone. Normal or STZ-diabetic rats
used to prepare test medications. Values (mean ± SD) were obtained for each
d normal rats, respectively. cP < 0.05 and dP < 0.01 compared to the values of
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follows [22]: 0, normal glomeruli; 1, matrix expansion
occurred in up to 50% of a glomerulus; 2, matrix expan-
sion occurred in 50 to 75% of a glomerulus; 3, matrix ex-
pansion occurred in 75 to 100% of a glomerulus. Scores
were assigned for at least 30 glomeruli from kidney
slices from each animal, and the means were calculated.
Each slide was scored by a pathologist who was unaware
of the experimental details.
Immunohistochemistry
Formalin-fixed, paraffin-embedded kidney tissue sections
were used for immunohistochemical staining. After depar-
affinization and hydration, the slides were washed in(A)


























Figure 1 Effects of treatments on the renal histology. (A) Representativ
rats treated for eight weeks with ruscogenin (RUS) or rosiglitazone (Rosi). S
with 3 mg/kg RUS (STZ + RUS) or 5 mg/kg RGZ (STZ + Rosi). Normal (norm
were administered the same volume of vehicle (Veh) used to prepare test me
mesangial expansion index for each group. Values (mean ± SD) were obtained
normal rats (normal + Veh). cP < 0.05 and dP < 0.01 compared to vehicle-treateTris-buffered saline (TBS; 10 mmol/l Tris HCl, 0.85% NaCl,
pH 7.2). Endogenous peroxidase activity was quenched by
incubating the slides in methanol and 0.3% H2O2 in metha-
nol. After overnight incubation with mouse mono-
clonal anti-monocyte/macrophage antibody (anti-ED-1)
(Santa Cruz Biotechnology Inc. CA, USA; Cat. No. sc-
59103), goat polyclonal anti-ICAM-1 antibody (Santa Cruz
Biotechnology, Inc.; Cat. No. sc-1511), rabbit polyclonal
nti-MCP-1 antibody (Abcam plc, Cambridge, UK; Cat. No.
ab7202), mouse monoclonal anti-TGF-β1 antibody (Santa
Cruz Biotechnology, Inc.; Cat. No. sc-52893), or rabbit poly-
clonal anti-fibronectin antibody (Abcam plc, Cat. No.
ab2413) at 4°C, the slides were washed in TBS. Horseradish





e photomicrographs of H&E-stained kidney sections from STZ-diabetic
TZ-diabetic rats were dosed by oral gavage once daily for eight weeks
al + Veh) or STZ-diabetic rats receiving vehicle treatment (STZ + Veh)
dications. Magnification bars = 100 μm (B) Results of quantification of the
for each group of 5 animals. bP < 0.01 compared to vehicle-treated
d STZ-diabetic rats (STZ + Veh), respectively.
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additional 1 hour. The slides were washed in TBS, incubated
with diaminobenzidine tetrahydrochloride as the substrate,
and counterstained with hematoxylin. A negative control
without primary antibody was included in the experiment to
verify antibody specificity.
Sections were counterstained with haematoxylin for
15 seconds. Brownish yellow granular or linear deposits
were interpreted as positive areas. Intraglomerular ED1-
positive cells were counted in 30 glomeruli per animal at
400 ×magnification by two independent observers with no
prior knowledge of the experimental design [23]. The aver-
age number per glomerulus was used. Semi-quantitative(A)































Figure 2 Effects of treatments on macrophage infiltration. (A) Immuno
tissues of STZ-diabetic rats treated for eight weeks with ruscogenin (RUS) or ro
for eight weeks with 3 mg/kg RUS (STZ + RUS) or 5 mg/kg RGZ (STZ + Rosi). N
(STZ + Veh) were administered the same volume of vehicle (Veh) used to
bars = 50 μm. (B) Quantified results are shown for number of macrophage
group of 5 animals. bP < 0.01 compared to vehicle-treated normal rats (no
STZ-diabetic rats (STZ + Veh), respectively.assessments of the immunostaining of ICAM-1, MCP-1,
TGF-β1, and fibronectin expression were scored using 4
levels, and an average value was obtained from analyses of
more than 30 glomeruli per rat. The degree of ICAM-1,
MCP-1, TGF-β1 and fibronectin expression in five rats
from each group was graded as follows: 0, absent or < 25%
staining; 1, 25% to 50% positive staining; 2, 50% to 75%
positive staining; and 3, > 75% positive staining [22].
Western blotting
Protein extraction of isolated kidney was performed as
follows [24]. The sample was homogenized in ice-cold





histochemical staining for macrophage (ED-1-positive) cells in the renal
siglitazone (Rosi). STZ-diabetic rats were dosed by oral gavage once daily
ormal (normal + Veh) or STZ-diabetic rats receiving vehicle treatment
prepare test medications. Arrows indicate positive areas. Magnification
s (ED-1-positive cells). Values (mean ± SD) were obtained for each
rmal + Veh). cP < 0.05 and dP < 0.01 compared to vehicle-treated







































Figure 3 Effects of treatments on cytokines levels in renal
tissues of rats. STZ-diabetic rats treated for eight weeks with rusco-
genin (RUS) or rosiglitazone (Rosi). STZ-diabetic rats were dosed by
oral gavage once daily for eight weeks with 3 mg/kg RUS (STZ +
RUS) or 5 mg/kg RGZ (STZ + Rosi). Normal (normal + Veh) or STZ-
diabetic rats receiving vehicle treatment (STZ + Veh) were adminis-
tered the same volume of vehicle (Veh) used to prepare test medica-
tions. Values (mean ± SD) were obtained for each group of 8
animals. aP < 0.05 and bP < 0.01 compared to the values of vehicle-
treated normal rats, respectively. cP < 0.05 and dP < 0.01 compared
to the values of vehicle-treated STZ-diabetic rats, respectively.
Lu et al. BMC Complementary and Alternative Medicine 2014, 14:110 Page 6 of 12
http://www.biomedcentral.com/1472-6882/14/110(pH 7.8), 10 mmol/l KCl, 2 mmol/l MgCl2, 1 mmol/l
DTT, 0.1 mmol/l EDTA, 0.1 mmol/l phenylmethylsul-
fonylfluoride]. The cells were then lysed with 12.5 μl
10% Nonidet P-40. The homogenate was centrifuged,
and supernatant containing the cytoplasmic extracts
was stored frozen at −80°C. The nuclear pellet was
resuspendedin 25 μl ice-cold nuclear extraction buffer.
After 30 minutes of intermittent mixing, the extract
was centrifuged, and supernatants containing nuclear
extracts were secured.
Before immunoblotting, and the protein concentration
of each tissue was determined using a Bio-Rad protein
assay kit (Bio-Rad Laboratories, Japan) and BSA as a
standard, to ensure equal loading among lanes. Nnuclear
extracts (50 μg total protein) were separated on a 7.5-
15% polyacrilamide gel and electophoretically transferred
to nitrocellulose membrane. Membranes were blocked
with 5% non-fat dry milk in Tris-buffered saline Tween
(20 mmol/l Tris, pH 7.6, 137 mmol/l NaCl, and 0.1%
Tween 20) for 3 h at room temperature, and incubated
overnight at 4°C with the following primary antibodies:
p-NF-κB p65 (Ser276) (Santa Cruz Biotechnology Inc.;
Cat. No. sc-101749), NF-κB p65 (Cell Signaling Technol-
ogy, USA; Cat. No. 4764,). The level of lamin A (Santa Cruz
Biotechnology Inc.; Cat. No. sc-20680) was estimated for
equal loading of nuclear sample. Three times after washing
with Tris-buffered saline Tween 20 (TBST), incubation with
appropriate horseradish peroxidase-conjugated secondary
antibodies were performed for 1 h at room temperature.
After three additional TBST washes, the immunoreactive
bands were visualized by enhanced chemiluminescence
(Amersham Biosciences, Buckinghamshire, UK) accord-
ing to the manufacturer's instructions. Band densities
were determined using ATTO Densitograph Software
(ATTO Corporation, Tokyo, Japan). All experimental
sample values were then expressed relative to this ad-
justed mean value. Tissue sections were sampled from 4
independent experiments.
Statistical analysis
The results are presented as the mean ± standard devi-
ation (SD) for each group of animals at the number (n)
indicated. Statistical analysis was performed with one-way
analysis of variance (ANOVA). The Dunnett range post-
hoc comparisons were used to determine the source of
significant differences where appropriate. The renal mor-
phohistology and the morphologic analysis for PAS stain-
ing were analyzed statistically using the Kruskal-Wallis
Test and Dunn’s Multiple Comparisons Test. Values of P
< 0.05 were considered statistically significant.
Results and discussion
DN is characterized by pathophysiological changes in
glomerular hyperfiltration, renal hypertrophy, tubularfunction and then progress to proteinuria and reduction
of glomerular filtration rate [2]. Accumulating evidence
suggests that these clinical features can be linked, at
least in part, to pathologic changes in the glomerular
ECM [2]. STZ-diabetic rats showed an increase in 24-hour
urine volume, accompanied by increase in urine protein
excretion (Table 1). After eight weeks of ruscogenin or
rosiglitazone treatment, 24-hour urine volume and 24-
hour urine protein excretion for STZ-diabetic rats were
markedly less than those of their vehicle-treated coun-
terparts (Table 1). In addition, Scr and BUN levels in
STZ-diabetic rats were obviously higher than in rats
from the normal control group. These levels were ef-
fectively reduced in STZ-diabetic rats treated for eight
weeks with ruscogenin relative to levels in their vehicle-
counterparts (Table 1). In particular, increased Ccr in
STZ-diabetic rats was obviously observed after eight
weeks of ruscogenin or rosiglitazone treatment (Table 1).
We also found that the kidney/body weight ratio was re-
duced by ruscogenin after 8 weeks treatment, suggest-
ing that this compound may prevent diabetes-induced
kidney enlargement. The previous study has been indi-
cated that prevention of glomerular hypertrophy ame-
liorates the development of DN, including proteinuria
and podocytopenia [25]. Thus, we demonstrated treat-
ment with ruscogenin attenuated DN syndrome charac-
terized by proteinuria and the loss of renal function in
STZ-diabetic rats. Considering the effects of 3.0 mg/kg/































































Figure 4 (See legend on next page.)
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Figure 4 Effects of treatments on protein expressions of MCP-1 and ICAM-1 in the renal tissues of rats. (A) Immunohistochemical staining
for MCP-1 and ICAM-1 in renal tissues of STZ-diabetic rats treated for eight weeks with ruscogenin (RUS) or rosiglitazone (Rosi). STZ-diabetic rats were
dosed by oral gavage once daily for eight weeks with 3 mg/kg RUS (STZ + RUS) or 5 mg/kg RGZ (STZ + Rosi). Normal (normal + Veh) or STZ-diabetic
rats receiving vehicle treatment (STZ + Veh) were administered the same volume of vehicle (Veh) used to prepare test medications. Arrows indicate
positive areas. Magnification bars = 50 μm. (B) Semi-quantitative assessments of the immunostaining were scored using 4 levels, and an average value
was obtained from analyses of more than 30 glomeruli per rat. Values (mean ± SD) were obtained for each group of 5 animals. bP < 0.01 compared to
vehicle-treated normal rats (normal + Veh). cP < 0.05 and dP < 0.01 compared to vehicle-treated STZ-diabetic rats (STZ + Veh), respectively.
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rosiglitazone, the kidney in STZ-diabetic rats receiving
3.0 mg/kg/day ruscogenin treatment was further iso-
lated to delineate the potential underlying mechanisms.
The STZ-diabetic rats showed focal mesangial matrix
expansion compared to normal control rats (Figure 1A).
Quantification of renal pathology showed that mean
mesangial area was significantly increased in diabetic
rats, however, treatment with rosiglitazone for 8 weeks
markedly ameliorated mesangial expansion when com-
pared with the untreated STZ-diabetic rats (Figure 1B).
After eight weeks of treatment, enlargement of the
mesangia in glomeruli was mildly attenuated in the
STZ-diabetic rats treated with 3.0 mg/kg/day of rusco-
genin. Quantitative analysis also showed that there was
a marked decrease in the percentage of mesangial ex-
pansion in STZ-diabetic rats treated with 3.0 mg/kg/
day ruscogenin compared with their vehicle-treated
counterparts (Figure 1B). The kidney-protective effects
of ruscogenin were further confirmed by the finding
that ruscogenin treatment attenuated the structural
abnormalities of DN.
Among the many potential pathogenetic mechanisms
that are responsible for the development of diabetic kidney
disease, an inflammatory mechanism has been suggested
to be involved in the development of DN [3]. Macro-
phages are key inflammatory cells mediating kidney in-
flammation in experimental and human diabetes. In
diabetes, macrophage accumulation and activation are
associated with prolonged hyperglycemia, glomerular
immune complex deposition, increased chemokine pro-
duction, and progressive fibrosis [17,18]. Activated macro-
phages elaborate a host of proinflammatory, profibrotic,
and antiangiogenic factors. Using accumulation of ED-1 as
a marker of macrophage activation [26], we have demon-
strated that increased macrophage activation in the glom-
eruli of kidney tissue from STZ-diabetic rats (Figure 2). In
contrast, kidneys from control rats showed no significant
macrophage infiltration (Figure 2). Treatment of STZ-
diabetic rats with rosiglitazone or ruscogenin (3.0 mg/kg/
day) for eight weeks caused a 33.8 ± 4.6% and 43.4 ± 3.9%
reduction of macrophage influx, respectively, relative to
that in their vehicle-treated counterparts (Figure 2). The
renal expression of inflammatory cytokines such as TNF-
α, IL-6 and IL-1β were demonstrated to increase indiabetes, contributing to the development of DN [27].
Along with the effects on macrophages, there was a reduc-
tion in the upregulated protein expression of TNF-α, IL-6
and IL-1β from kidneys of STZ-diabetic rats receiving rus-
cogenin (3.0 mg/kg/day) treatment (Figure 3). Thus, we
believe that the anti-inflammatory effects of ruscogenin,
through the inhibition of macrophage infiltration, might
provide a renoprotective effect in the STZ- diabetic
model.
ICAM-1 is a known important downstream inflamma-
tory factor whose overexpression promotes inflammatory
cells, including mononuclear macrophage infiltration into
glomeruli and renal interstitium, as well as accelerates
glomerular sclerosis in diabetes [6,7]. In addition to acting
as a chemoattractant cytokine, MCP-1 may be involved in
the inflammatory response by activating the macrophages
from the circulation to the local kidney and then promote
the expression of other proinflammatory cytokines to aug-
ment the accumulation of extracellular matrix [6,7]. The
renal MCP-1 and ICAM-1 proteins were 2.6 and 2.4 fold
higher in STZ-diabetic rats compared with normal rats,
respectively. These increases were ameliorated by 30.4 ±
4.8% and 37.3 ± 5.2%, respectively, after eight weeks of
treatment with rosiglitazone (Figure 4). Treatment of
STZ-diabetic rats with 3.0 mg/kg/day ruscogenin for eight
weeks resulted in a 20.2 ± 3.8% and 27.4 ± 4.9% reduction
of renal MCP-1 and ICAM-1 protein expression, respect-
ively, compared with that in vehicle-treated counterparts
(Figure 4). The inhibitory effect of ruscogenin on MCP-1
and ICAM-1 may be partially due to the decreased in-
filtration of monocytes/macrophages. Therefore, a possible
mechanism for preventing the progression of renal disease
may involve the effect of ruscogenin to attenuate inflam-
mation, by reducing the release of inflammatory mediators
and/or inhibiting the expression of adhesion molecules in
the diabetic kidney.
The profibrotic factor such as TGF-β1 is recognized as
another important factor in the pathogenesis of DN by
mediating inflammatory response, which aggravates ex-
tracellular matrix accumulation, as well as accelerates
glomerular fibrosis in diabetes [28]. Thus, the inhibition
of TGF-β1 expression benefits the treatment of diabetic
kidney disease by alleviating matrix accumulation. Our re-
sults show that renal TGF-β1 protein levels were 2.4-fold































































Figure 5 (See legend on next page.)
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Figure 5 Effects of treatments on protein expressions of TGF-β1 and fibronectin in renal tissues of rats. (A) Immunohistochemical
staining for TGF-β1 and fibronectin in renal tissues of STZ-diabetic rats treated for eight weeks with ruscogenin (RUS) or rosiglitazone (Rosi).
STZ-diabetic rats were dosed by oral gavage once daily for eight weeks with 3 mg/kg RUS (STZ + RUS) or 5 mg/kg RGZ (STZ + Rosi). Normal
(normal + Veh) or STZ-diabetic rats receiving vehicle treatment (STZ + Veh) were administered the same volume of vehicle (Veh) used to prepare
test medications. Arrows indicate positive areas. Magnification bars = 50 μm. (B) Semi-quantitative assessments of the immunostaining were
scored using 4 levels, and an average value was obtained from analyses of more than 30 glomeruli per rat. Values (mean ± SD) were obtained for
each group of 5 animals. bP < 0.01 compared to vehicle-treated normal rats (normal + Veh). cP < 0.05 and dP < 0.01 compared to vehicle-treated
STZ-diabetic rats (STZ + Veh), respectively.
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4.2% (Figure 5). The STZ-induced upregulation of TGF-
β1 protein was reduced by 40.2% relative to that in
vehicle-treated STZ-diabetic rats after eight weeks of
treatment with ruscogenin (Figure 5). Furthermore, fibro-
nectin, a major ECM protein, was induced in diabetic rats
but ameliorated by ruscogenin (Figure 5). Therefore,
we propose the anti-inflammatory, anti-fibrotic, and
anti-hypertrophic effects of ruscogenin in DN may be
attributable to the suppression of MCP-1 and ICAM-1
expression, by which inflammatory cell infiltration is
abrogated, in turn ameliorating ECM accumulation.
NF-κB is a ubiquitous and well-known transcription
factor responsible for regulating the expressions of genes
that are involved in inflammatory pathways such as pro-
inflammatory cytokines, chemokines and adhesion mo-
lecules [29]. Ruscogenin has been reported to have
anti-inflammatory activity through inhibiting NF-κB
activity [14,15]. However, it was unknown whether the
inhibited effects of ruscogenin on inflammatory processes

























Figure 6 Effects of treatments on NF-κB activity (A) and phosphorylat
eight weeks with ruscogenin (RUS) or rosiglitazone (Rosi). STZ-diabetic rats
RUS (STZ + RUS) or 5 mg/kg RGZ (STZ + Rosi). Normal (normal + Veh) or STZ-d
the same volume of vehicle (Veh) used to prepare test medications. The m
that of NF-κB. The level of lamin A was estimated for equal loading of nuc
animals. aP < 0.05 and bP < 0.01 compared with vehicle-treated normal rat
vehicle-treated STZ-diabetic rats (STZ + Veh), respectively.activation. NF-κB undergoes phosphorylation on serine
276 in its p65 subunit and associates with surrounding
chromatin components. It subsequently binds with
DNA and promotes the transcription of proinflamma-
tory cytokines, chemokines and adhesion molecules
[29]. Thus, detection of the phosphorylated p65 sub-
unit of NF-κB was effective for evaluating NF-κB acti-
vation [29]. Ruscogenin significantly inhibited NF-κB
activation in kidney of diabetic rats, as evidenced by
a decrease in NF-κB activity and downregulation of
phosphorylated NF-κB (Figure 6). In the present study,
ruscogenin exhibited anti-inflammatory effects through
inhibiting NF-κB pathway, which was consistent with
the previous study [14,15]. These results suggest that
the inhibition of ruscogenin on renal inflammation in
diabetic rats may be related to suppression of activation
and overexpression of NF-κB.
It is widely known that activation of peroxisome
proliferator-activated receptor (PPAR)γ attenuates the NF-
κB-mediated transcriptional activation of proinflammatory

























ed NF-κB (B) in renal tissues of rats. STZ-diabetic rats treated for
were dosed by oral gavage once daily for eight weeks with 3 mg/kg
iabetic rats receiving vehicle treatment (STZ + Veh) were administered
ean density values of p-NF-κB were expressed as ratios relative to
lear sample. Values (mean ± SD) were obtained for each group of 5
s (normal + Veh), respectively. cP < 0.05 and dP < 0.01 compared to
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http://www.biomedcentral.com/1472-6882/14/110agonist exerts a renoprotective effect through an anti-
inflammatory mechanism in DN [19]. In the present
study, the renoprotective effect of ruscogenin seems to be
as effective as that produced by the standard drug rosi-
glitazone, an agonist of PPARγ. Unlike the effects of
rosiglitazone, we found that ruscogenin administration
did not inhibit the HgbA1c nor lower hyperglycemia in
STZ-diabetic rats (Table 1). Although ruscogenin be a
ligand of PPARγ needs to be further investigated, the
above results suggest that beneficial effect of ruscogenin
in rats with DN is not mediated by its antihyperglyce-
mic activity. This might be important, as we provided a
data supporting that an anti-inflammatory intervention
was effective in DN even without altering the blood glu-
cose level.
Using a metabolism coefficient of 6.25 to convert
the effective daily oral dose of ruscogenin for rat (3.0
mg/kg) into a clinical dose, assuming an average adult
body weight of 60 kg [31], we estimated a daily oral
dose of ruscogenin for humans to be approximately
32 mg. Due to different metabolism in humans and
rats, the results come from rat studies cannot
generalize to human. The placebo controlled human
studies are required to find the usability of rusco-
genin in human indication for DN.
Conclusions
We have shown that the anti-inflammatory and anti-
fibrotic effects of ruscogenin in DN may be attributable to
prevention of NF-κB activation, by which inflammatory
cell infiltration is abrogated, in turn ameliorating ECM
accumulation. This study provides an important pharma-
cological and therapeutic basis for the treatment of DN.
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